2C-I

2C-I (2,5-dimethoxy-4-iodophenethylamine) is a synthetic substituted phenethylamine and serotonergic hallucinogen first synthesized by Alexander Shulgin in 1977 and described in his 1991 publication PiHKAL (Phenethylamines I Have Known and Loved). The compound belongs to the 2C family, a series of 2,5-dimethoxy-substituted phenethylamines named by Shulgin for the two-carbon ethylamine bridge between the aromatic ring and the terminal amine, and is distinguished from its congeners by a single iodine substituent at the 4-position of the dimethoxyphenyl ring. This halogen substitution confers high binding affinity at the serotonin 5-HT2A receptor (Ki approximately 0.7 to 9.3 nanomolar depending on assay system and radioligand), full agonist efficacy in phospholipase C-coupled signaling (EC50 approximately 10 nanomolar, 102 percent of serotonin maximum in the inositol phosphate accumulation assay), and a pharmacologically distinctive biased agonism profile in which the compound acts as a full agonist in the phospholipase C pathway but as an antagonist in the arachidonic acid release pathway at the same receptor [1, 2].

The primary pharmacological interest in 2C-I centers on three domains. First, as a serotonergic hallucinogen, 2C-I produces dose-dependent head twitch responses in rodents (ED50 approximately 0.83 mg/kg in C57BL/6J mice) that are completely blocked by the selective 5-HT2A antagonist M100,907, and fully substitutes for the discriminative stimulus of both N,N-dimethyltryptamine (ED50 0.68 mg/kg) and lysergic acid diethylamide (ED50 1.66 mg/kg) in trained rats [1, 3]. These behavioral signatures confirm classical hallucinogenic activity mediated exclusively through the 5-HT2A receptor. Second, 2C-I demonstrated the highest anti-inflammatory potency of any compound assessed in a large-scale screen of serotonergic psychedelics for inhibition of tumor necrosis factor alpha (TNF-alpha)-mediated inflammatory gene expression, exceeding the potency of the reference compound (R)-DOI, which itself inhibits TNF-alpha-induced proinflammatory markers at IC50 values of 10 to 20 picomolar [4, 5, 6]. The anti-inflammatory and hallucinogenic activities appear to be dissociable, operating through distinct downstream signaling cascades from the same 5-HT2A receptor. Third, 2C-I serves as the direct structural parent of the N-benzyl derivative 25I-NBOMe, a superpotent 5-HT2A agonist with substantially greater receptor affinity (Ki 0.044 nanomolar) that has emerged as a compound of forensic and toxicological concern [1].

The compound is metabolized principally by monoamine oxidase A and B (MAO-A and MAO-B), with secondary contributions from O-demethylation at the 2- and 5-positions followed by N-acetylation or deamination with subsequent oxidation or reduction [7, 8]. CYP450 isoenzymes play a minor role in 2C-I biotransformation relative to the MAO-dependent pathway, distinguishing the metabolic disposition of the 2C series from that of the structurally related amphetamine-class phenethylamines [8]. The compound is inactive as a monoamine releasing agent and shows negligible activity at dopamine and norepinephrine transporters, with weak affinity at the serotonin transporter (Ki approximately 950 nanomolar) [2].

2C-I was placed in Schedule I of the United States Controlled Substances Act on July 9, 2012, under the Synthetic Drug Abuse Prevention Act. It is a Class A substance in the United Kingdom, a Schedule III substance in Canada, and a Schedule 9 prohibited substance in Australia. Clinical toxicology reports document serotonin syndrome, recurrent seizures, hypertension, tachycardia, and hyperthermia following recreational use, predominantly by insufflation [9]. No approved medical indication exists. The compound is available from research chemical suppliers as the hydrochloride salt for in vitro and in vivo investigational use. This monograph reviews the chemistry, synthesis, receptor pharmacology, metabolic disposition, preclinical behavioral and anti-inflammatory pharmacology, clinical toxicology, sourcing and handling, stack interactions, adverse events, and a comparative assessment of five structurally related phenethylamine serotonin receptor agonists against 2C-I on five competency standards.